Clinical trials
Carcinoma, Hepatocellular trials in South Korea with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
53 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2007 | 2 |
| 2009 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 4 |
| 2017 | 5 |
| 2018 | 4 |
| 2019 | 2 |
| 2020 | 7 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 21 |
| Unknown status | 20 |
| Recruiting | 5 |
| Active, not recruiting | 4 |
| Terminated | 1 |
| Not yet recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Seoul National University Hospital | 32 |
| Asan Medical Center | 4 |
| Samsung Medical Center | 3 |
| Yonsei University | 3 |
| National Cancer Center, Korea | 2 |
| Ethicon, Inc. | 1 |
| Gangneung Asan Hospital | 1 |
| Hallym University Medical Center | 1 |
| JOON-IL CHOI | 1 |
| Jonggi Choi | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Hepatocellular | 53 |
| Liver Cirrhosis | 7 |
| Recurrence | 3 |
| Liver Neoplasms | 2 |
| Adenoma, Islet Cell | 1 |
| Blood Loss, Surgical | 1 |
| Body Weight | 1 |
| Breast Neoplasms | 1 |
| Carcinoma | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
Trials
Showing 1 to 25 of 53. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.